Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes

11 May 2015

• By Sue Sutter

Related Content

“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles

26 Nov 2012

<em>Zykadia</em> Expedited Timeline Challenged By Late-Breaking GMP Concern

07 Jul 2014

<em>Sovaldi</em> NDA Review Marred By Manufacturing Compliance Issues

22 Apr 2014

Totality Of ‘Breakthrough’ Evidence Guides FDA Designation Decisions

04 May 2015

Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First

04 May 2015

Related Companies

Bluebird Bio

Gilead Sciences, Inc.

Novartis AG

Additional Topics

United States Regulation Manufacturing BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.